Evicenter
P&T meetings

Zipalertinib (CLN-081)

EGFR exon 20 insertion-mutated non-small-cell lung cancer

Also known as TAS6417
Manufacturer
Taiho Oncology
Regulatory submission
NDA submitted February 2026
Launch
Not announced
Last updated
75 sources

Product information and disease descriptionProduct description

Product information

20 evidence topics · 23 sources

Average sales price and wholesale acquisition cost

Not applicable.

Contraindications/Warnings/Precautions/Adverse effects
Warnings and precautions

Not applicable.

Effect of Zipalertinib on quality measures

No evidence found.

Product comparison